Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) diseases through the development and commercialization of medicines. CY6463 is the key of Co.'s CNS portfolio with ongoing clinical programs in Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes and Alzheimer's disease with vascular pathology. Praliciguat is an orally administered, once-daily systemic soluble guanylate cyclase (sGC) stimulator that was evaluated in studies for adult participants with diabetic nephropathy and heart failure with preserved ejection fraction. Olinciguat is an orally administered vascular sGC stimulator. The CYCN stock yearly return is shown above.
The yearly return on the CYCN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CYCN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|